Evaluation of the effects of the Probiotics on the Expression of TGF-ß, IL-17, and IL-6 in Children with Acute Lymphoblastic Leukemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260121068632N1

Enrollment

Registered

2026-01-24

Start date

2026-02-04

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation.

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive Lactocare capsules at a dose of 500 mg per day for 14 days. Intervention 2: Control group: The control group will re

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Confirmation of Acute Lymphoblastic Leukemia (ALL) based on the patient’s medical history and diagnostic test results. The patients have undergone routine treatment for approximately one year and have entered the maintenance phase, with the disease being controllable. Age range: 5 to 15 years. Patients must be able to swallow medication. Patients should have no history of radiotherapy within six months prior to the study, as radiotherapy can cause severe gastrointestinal complications, for which physicians prescribe famotidine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Inflammation. Timepoint: At the start of the study and on day 14. Method of measurement: Laboratory methods such as ELISA, PCR, and flow cytometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAziz Eghbali

Tehran University of Medical Sciences

aziz_eghbali@yahoo.com+98 21 2222 2041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026